Clinical Scorecard: Evaluating the Impact of Levothyroxine on Cardiovascular Health in Older Adults in the United Kingdom: A Cohort Analysis

At a Glance

Key Highlights

• Levothyroxine therapy in older adults with SCH showed a protective effect against cardiovascular events (HR 0.91).
• Levothyroxine treatment was associated with increased risk of bone events (fragility fractures, osteoporosis) and all-cause mortality.
• TSH levels naturally rise with age, suggesting the need for age-specific reference intervals to avoid overdiagnosis and overtreatment.

Guideline-Based Recommendations

Diagnosis

• Define SCH by elevated TSH with normal free thyroxine levels.
• Consider age-specific TSH reference intervals rather than standard 0.4 to 4.0/4.5 mU/L for older adults.

Management

• Treat overt hypothyroidism with levothyroxine as standard.
• For SCH, initiate levothyroxine if TSH >10 mU/L and symptoms are present, per European guidelines.
• Exercise caution with levothyroxine in older adults due to potential risks.

Monitoring & Follow-up

• Monitor cardiovascular events, bone health (fragility fractures, osteoporosis), and mortality risk during levothyroxine therapy.
• Avoid overtreatment leading to suppressed TSH levels.

Risks

• Levothyroxine therapy may increase risk of bone events and all-cause mortality in older adults with SCH.
• Overtreatment can lead to adverse cardiovascular and fracture risks.

Patient & Prescribing Data

53,899 UK primary care patients older than 50 years with SCH; 37% treated with levothyroxine.

Levothyroxine reduced cardiovascular events but increased bone events and mortality, indicating a risk-benefit trade-off.

Clinical Best Practices

• Assess TSH levels with consideration of age-related reference ranges before diagnosing SCH.
• Discuss potential benefits and harms of levothyroxine therapy with older patients.
• Individualize treatment decisions balancing cardiovascular protection against bone and mortality risks.
• Regularly monitor patients on levothyroxine for signs of overtreatment and adverse outcomes.

References

• The Health Improvement Network (THIN) database
• European Guidelines for Subclinical Hypothyroidism
• TRUST Study on Levothyroxine in Older Adults
• ACEL-UK Study Protocol